Sanofi/$SNY
13:30
03:10
16:45
06:25
20:00
1D1W1MYTD1Y5YMAX
About Sanofi
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Ticker
$SNY
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Employees
82,878
ISIN
US80105N1054
Website
Sanofi Metrics
BasicAdvanced
$117B
8.19
$5.81
0.48
$1.60
3.36%
Price and volume
Market cap
$117B
Beta
0.48
52-week high
$60.12
52-week low
$45.80
Average daily volume
2.2M
Dividend rate
$1.60
Financial strength
Total debt to equity
23.008
Interest coverage (TTM)
17.14%
Profitability
EBITDA (TTM)
14,003.971
Gross margin (TTM)
70.96%
Net profit margin (TTM)
13.95%
Operating margin (TTM)
20.80%
Effective tax rate (TTM)
20.10%
Revenue per employee (TTM)
$622,500
Management effectiveness
Valuation
Price to earnings (TTM)
8.189
Price to revenue (TTM)
1.141
Price to book
1.34
Price to tangible book (TTM)
5.25
Dividend yield (TTM)
3.36%
Forward dividend yield
3.36%
Growth
Revenue change (TTM)
-2.42%
Earnings per share change (TTM)
39.56%
3-year revenue growth (CAGR)
3.84%
10-year revenue growth (CAGR)
2.56%
3-year earnings per share growth (CAGR)
-1.65%
10-year earnings per share growth (CAGR)
4.46%
What the Analysts think about Sanofi
Analyst ratings (Buy, Hold, Sell) for Sanofi stock.
Bulls say / Bears say
Sanofi's acquisition of Vigil Neuroscience for $470 million aims to strengthen its neurological drug portfolio, particularly in Alzheimer's treatment, potentially enhancing future revenue streams. (reuters.com)
The launch of a new vaccine manufacturing facility in Vietnam, in partnership with VNVC, is expected to produce 100 million doses annually by the end of 2027, expanding Sanofi's global production capacity. (reuters.com)
Sanofi's drug Dupixent saw a 29.2% increase in sales, reaching €3.30 billion, indicating strong demand and contributing significantly to the company's revenue growth. (aol.com)
Sanofi's shares hit a 52-week low after issuing a 2024 forecast that fell significantly below expectations, partly due to increased R&D spending and a higher tax rate. (seekingalpha.com)
The company announced it will no longer target a 32% business operating income margin for 2025, raising concerns about long-term profitability. (seekingalpha.com)
Sanofi plans to spin off its consumer products division as a publicly traded entity, which could lead to short-term operational disruptions and investor uncertainty. (seekingalpha.com)
Data summarised monthly by Lightyear AI. Last updated on 27 May 2025.
Sanofi Financial Performance
Revenues and expenses
Sanofi Earnings Performance
Company profitability
Sanofi News
AllArticlesVideos
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
WSJ·8 hours ago
Press Release: Dupixent approved in the US as the only targeted medicine to treat patients with bullous pemphigoid
GlobeNewsWire·9 hours ago
RFK Jr.'s new vaccine advisors will vote on flu shots containing mercury
CNBC·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sanofi stock?
Sanofi (SNY) has a market cap of $117B as of June 20, 2025.
What is the P/E ratio for Sanofi stock?
The price to earnings (P/E) ratio for Sanofi (SNY) stock is 8.19 as of June 20, 2025.
Does Sanofi stock pay dividends?
Yes, the Sanofi (SNY) stock pays dividends to shareholders. As of June 20, 2025, the dividend rate is $1.59864 and the yield is 3.36%. Sanofi has a payout ratio of 0% on a trailing twelve-month basis.
When is the next Sanofi dividend payment date?
The next Sanofi (SNY) dividend payment date is unconfirmed.
What is the beta indicator for Sanofi?
Sanofi (SNY) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.